CXCR4 was also expressed in a subset of tumour cells from a KRASG13R mutant NSCLC patient-derived xenograft (PDX) model, featuring resistance to cisplatin and trametinib and partial resistance to paclitaxel (TM00226, The Jackson Laboratory PDX Database). Here, CXCR4 is linked to non-small cell lung carcinoma.